Oramed Pharmaceuticals In... (ORMP)
2.35
-0.01 (-0.42%)
At close: Jan 15, 2025, 1:41 PM
undefined% (undefined)
| Bid | 2.34 |
| Market Cap | 94.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.11 |
| PE Ratio (ttm) | 21.32 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.35 |
| Volume | 40,783 |
| Avg. Volume (20D) | 149,298 |
| Open | 2.40 |
| Previous Close | 2.36 |
| Day's Range | 2.33 - 2.40 |
| 52-Week Range | 2.00 - 3.67 |
| Beta | undefined |
About ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptid...
Industry Biotechnology
Sector Healthcare
IPO Date May 1, 2007
Employees 13
Stock Exchange NASDAQ
Ticker Symbol ORMP
Website https://www.oramed.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ORMP stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Oramed Pharmaceuticals Inc. is scheduled to release its earnings on Jan 21, 2025,
during market hours.
Analysts project revenue of $0, reflecting a 0% YoY and earnings per share of -0.07, making a -12.50% decrease YoY.
Analysts project revenue of $0, reflecting a 0% YoY and earnings per share of -0.07, making a -12.50% decrease YoY.
6 months ago ·
Source
+14.73%
Oramed Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
